EUVIMEDScopri EUVIMED
Fallbericht

Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors

Shu-Yi Guo, Jian Wang, Jian-Pei Fang, Jia-Ying Lei iD, Xiao-Qin Wu, Kun-Yin Qiu iD, Dun-Hua Zhou iD

Pediatric Blood & Cancer · 2024-12 · 71 (12)

DOI: 10.1002/pbc.31340 ↗

At a glance

Fallbericht in Pediatric Blood & Cancer, published online on 2024-09-27. Written by Shu-Yi Guo and 6 co-authors. Institution: Department of Hematology/Oncology, Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Major MEDLINE topics: Lymphohistiocytosis, Hemophagocytic, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Immune Checkpoint Inhibitors. Cited 5 times so far (Crossref); 23 references. Funded by: Basic Research Project (Dengfeng Hospital) jointly funded by Universities (Institutes) in Guangzhou, Sun Yat-sen Pilot Scientific Research Fund, Guangdong Basic and Applied Basic Research Foundation.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Purpose

Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH) is a type of pediatric HLH that occurs frequently in Asia. Although immunochemotherapy based on etoposide and hormone has improved survival rates, there are still about 30% of HLH patients that do not respond. The objective of the article is to examine the efficacy and safety of programmed cell death protein 1 (PD‐1) inhibitors for children with relapsed/refractory (r/r) EBV‐HLH.

Methods

A retrospective case note review of four pediatric patients with r/r EBV‐HLH who were treated with PD‐1 inhibitors at Sun Yat‐sen Memorial Hospital, Sun Yat‐sen University.

Results

All four patients responded to PD‐1 inhibitors and achieved partial response after their first infusion. Plasma EBV DNA copy number and HLH‐related monitoring indicators decreased in all of these patients. All patients received allogeneic hematopoietic stem cell transplantation (allo‐HSCT), and two were still alive at the last follow‐up on December 30, 2022. Two patients died because of transplantation‐related complications. Serious side effects included increased liver enzymes and edema in two patients.

Conclusion

PD‐1 inhibitors are an effective salvage therapy and can provide a bridge to allo‐HSCT for pediatric patients with r/r EBV‐HLH. However, side effects should be monitered.

Subjects

MeSH terms (MEDLINE)

Lymphohistiocytosis, HemophagocyticEpstein-Barr Virus InfectionsHerpesvirus 4, HumanImmune Checkpoint InhibitorsHumansMaleFemaleRetrospective StudiesChildChild, PreschoolProgrammed Cell Death 1 ReceptorHematopoietic Stem Cell TransplantationAdolescentPrognosisFollow-Up StudiesRecurrence

Author keywords

Epstein–Barr viruschildrenhemophagocytic lymphohistiocytosisprogrammed cell death protein 1 inhibitors

Substances

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Authors and institutions

  • Department of Hematology/Oncology, Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

ORCID profiles: Jia-Ying Lei, Kun-Yin Qiu, Dun-Hua Zhou

Funding

  • Basic Research Project (Dengfeng Hospital) jointly funded by Universities (Institutes) in Guangzhou
  • Sun Yat-sen Pilot Scientific Research Fund
  • Guangdong Basic and Applied Basic Research Foundation
  • Special topic of science and technology for agriculture and social development of Guangzhou key R & D plan
  • Bethune Medical Scientific Research Fund Project
  • Guangdong Medical Scientific Research Foundation
  • Guangzhou Basic and Applied Basic Research Foundation
  • Yat-sen Excellent Young Scientists Fund

Cite

APA

Guo, S. Y., Wang, J., Fang, J. P., Lei, J. Y., Wu, X. Q., Qiu, K. Y., & Zhou, D. H. (2024). Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors. Pediatric Blood & Cancer, 71(12). https://doi.org/10.1002/pbc.31340

Vancouver

Guo SY, Wang J, Fang JP, Lei JY, Wu XQ, Qiu KY, et al. Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors. Pediatric Blood & Cancer. 2024;71(12). doi:10.1002/pbc.31340

BibTeX
@article{Guo2024,
  author = {Guo, Shu-Yi and Wang, Jian and Fang, Jian-Pei and Lei, Jia-Ying and Wu, Xiao-Qin and Qiu, Kun-Yin and Zhou, Dun-Hua},
  title = {Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  volume = {71},
  number = {12},
  doi = {10.1002/pbc.31340}
}
Start for free →